ArticleGland surgery2025
Targeted axillary dissection in breast cancer patients with metastatic nodal disease: a prospective study on localization techniques and oncological outcomes.
Article in Gland surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03878017 (Feasibility of a Novel Method of Axilla Staging by Using Ultrasound Visible Clips to Mark the Involved Axillary Lymph Nodes Before Neoadjuvant Chemotherapy in Breast Cancer Patients), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Feasibility of a Novel Method of Axilla Staging by Using Ultrasound Visible Clips to Mark the Involved Axillary Lymph Nodes Before Neoadjuvant Chemotherapy in Breast Cancer Patients
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neoadjuvant chemotherapy followed by targeted axillary dissection (TAD) has been proposed as an alternative to axillary lymph node dissection (ALND) in breast cancer patients with metastatic nodal disease. However, there is lack of standardization of TAD technique. This study aimed to prospectively evaluate the effectiveness of various localization techniques in TAD and assess the oncological outcomes of TAD alone versus ALND. Methods: Breast cancer patients with histologically proven nodal metastasis (T1-4N1-2M0) and neoadjuvant chemotherapy were included. Patients were divided into three groups: TAD-alone, TAD with ALND, and upfront ALND. Localization techniques used during TAD were assessed and oncological outcomes were compared between the TAD alone and ALND groups. This study was registered with ClinicalTrials.gov (identifier: NCT03878017). Results: One hundred and twenty-three patients, of which 18, 18, 87 underwent TAD alone, TAD with ALND and upfront ALND respectively, were included. All localization techniques, such as skin marking, Savi Scout and radio-guided occult lesion localization (ROLL) resulted in 100% retrieval of the marked node. Single-agent sentinel node localization during TAD was feasible. After a median follow-up of 13 and 23 months for the TAD-alone and ALND groups respectively, there were no significant differences in their oncological outcomes. Conclusions: Various localization techniques, including the less studied skin marking and ROLL, were effective in TAD. During TAD, single agent may be used for sentinel node localization. TAD alone did not have inferior oncologic outcomes on short term follow-up and may replace ALND in patients with complete nodal pathological response after neoadjuvant chemotherapy. Our findings need validation in larger studies with longer follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.